(NASDAQ: FDMT) 4d Molecular Therapeutics's forecast annual revenue growth rate of 968.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.63%.
4d Molecular Therapeutics's revenue in 2025 is $17,000.On average, 4 Wall Street analysts forecast FDMT's revenue for 2025 to be $410,270,917, with the lowest FDMT revenue forecast at $92,455,418, and the highest FDMT revenue forecast at $781,248,282. On average, 2 Wall Street analysts forecast FDMT's revenue for 2026 to be $459,965,705, with the lowest FDMT revenue forecast at $87,832,647, and the highest FDMT revenue forecast at $832,098,762.
In 2027, FDMT is forecast to generate $1,058,845,675 in revenue, with the lowest revenue forecast at $924,554,180 and the highest revenue forecast at $1,193,137,169.